The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study
Launched by NHS GREATER CLYDE AND GLASGOW · Feb 26, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PARS Study is looking at how to better diagnose and monitor breathing problems in children, particularly those born prematurely or with other health issues. Many existing tools for tracking breathing and sleep are too big or uncomfortable for young children, making it hard to get accurate results. This study aims to test a new, smaller, and wireless device that can help monitor breathing patterns in infants and children, especially those at risk for sleep disordered breathing (SDB). By finding better ways to diagnose these issues early, the hope is to improve health outcomes for these vulnerable children.
To participate in the study, children from newborns to age 16 who are undergoing sleep monitoring or are in a neonatal unit may be eligible. Parents or guardians must be willing to give consent for their participation. Participants will wear the new device to help researchers gather important information about their breathing patterns during sleep. This study is important because it aims to create more accessible diagnostic tools for children who struggle with current methods, ultimately leading to better care and support for those with breathing challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Group 1 - CR-poly group
- • Patient undergoing overnight CR-poly
- • Age birth to \>=16 years
- • Are willing and able to give informed assent/consent or have available next of Kin to provide informed consent on the participant\'s behalf
- • Able (in the Investigators opinion) to comply with all study requirements
- • Can speak and read English
- • Group 2 - Apnoea group
- • Inpatient in neonatal unit
- • Age birth (from 30 weeks gestational age) to term corrected
- • Parents willing and able to give informed consent
- • Able (in the Investigators opinion) to comply with all study requirements
- • Can speak and read English
- • Group 3- VT Group attending epilepsy monitoirng unit
- • Inpatient receiving video-telemetry epilepsy monitoring unit
- • Age birth to \<16 years
- • Parents willing and able to give informed consent
- • Able (in the Investigators opinion) and willing to comply with all study requirements
- • Can speak and read English
- Exclusion Criteria:
- • Group 1 - CR-poly group
- • Unable to provide consent and no next of kin to provide consent on participants behalf
- • Treating clinician deems patient inappropriate to be included in study
- • Group 2 - Apnoea group
- • No next of kin to provide consent on participants behalf
- • Treating clinician deems patient inappropriate to be included in study
- • Group 3- VT Group attending epilepsy monitoirng unit
- • Unable to provide consent and no next of kin to provide consent on participants behalf
- • Treating clinician deems patient inappropriate to be included in study
About Nhs Greater Clyde And Glasgow
NHS Greater Clyde and Glasgow is a leading healthcare organization dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor, it collaborates with a network of healthcare professionals and academic institutions to facilitate rigorous scientific studies aimed at evaluating new treatments and therapies. Committed to upholding the highest ethical standards and ensuring patient safety, NHS Greater Clyde and Glasgow plays a vital role in translating research findings into clinical practice, ultimately enhancing health outcomes for the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, Glasgow City, United Kingdom
Patients applied
Trial Officials
Ross J Langley, MBChB BSc PhD MRCPCH
Principal Investigator
NHS Greater Glasgow and Clyde
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported